

Amendments to the Claims

Please cancel claims 3-10, 13-16, and 21-40, and amend claims 2 and 11.

1. (Original) A PEGylated FGF-21 compound comprising an FGF-21 compound covalently attached to at least one PEG molecule, wherein each PEG is attached to the FGF-21 compound at a cysteine or lysine amino acid residue and wherein the PEGylated FGF-21 compound has extended time action compared to a non-PEGylated FGF-21 compound.

2. (Currently amended) The PEGylated FGF-21 compound of Claim 1 comprising the amino acid sequence as shown in SEQ ID NO:1 ~~covalently attached to a PEG molecule at one or more of the residues selected from the group consisting of lysine at position 56, 59, 69 or 122.~~, wherein said compound is selected from the group consisting of:

- (a) a compound covalently attached to a PEG molecule at one or more lysine residues at positions 56, 59, 69 or 122; and,
- (b) a compound covalently attached to a PEG molecule. at one or more amino acid residues selected from the group consisting of D25, D38, L58, K59, P60, K69, D79, H87, E91, E101, D102, L114, L116, K122, R126, P130, P133, or P140C, wherein said amino acid residue is substituted with a cysteine residue.

3. (Cancelled)

4. (Cancelled)

5. (Cancelled)

6. (Cancelled)

7. (Cancelled)

8. (Cancelled)

9. (Cancelled)

10. (Cancelled)

11. (Currently amended) The PEGylated FGF-21 compound of ~~Claim 6~~ Claim 2 wherein said PEG molecule has a molecular weight of about 20,000 to 40,000 daltons.

12. (Original) A pharmaceutical composition useful for treating a patient exhibiting obesity, type 2 diabetes, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, or metabolic syndrome comprising the following:

- a. A therapeutically effective amount of the PEGylated FGF-21 compound of Claim 1; and
- b. An acceptable pharmaceutical carrier.

13. (Cancelled)

14. (Cancelled)

15. (Cancelled)

16. (Cancelled)

17. (Original) A method for treating a patient exhibiting obesity, type 2 diabetes, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, or metabolic syndrome comprising administering to said patient in need of such treatment a therapeutically effective amount of the FGF-21 mutein of Claim 1.

18. (Original) The method of Claim 17 wherein said patient exhibits type 2 diabetes.

19. (Original) The method of Claim 17 wherein said patient exhibits obesity.

20. (Original) The method of Claim 17 wherein said patient exhibits metabolic syndrome.

21. (Cancelled)

22. (Cancelled)

23. (Cancelled)

24. (Cancelled)

25. (Cancelled)

26. (Cancelled)

27. (Cancelled)

28. (Cancelled)

29. (Cancelled)

30. (Cancelled)

31. (Cancelled)

- 32. (Cancelled)
- 33. (Cancelled)
- 34. (Cancelled)
- 35. (Cancelled)
- 36. (Cancelled)
- 37. (Cancelled)
- 38. (Cancelled)
- 39. (Cancelled)
- 40. (Cancelled)